| Document |
Document Title |
|
WO/2023/198181A1 |
Carbobicyclic nucleoside compounds useful for the treatment of coronavirus disease 2019 (COVID-19), RSV and other viral infections are provided. The carbobicyclic nucleoside compound may be a compound as set forth herein. Pharmaceutical ...
|
|
WO/2023/193341A1 |
Provided are a sphingolipid compound shown in formula (I), a liposome containing the sphingolipid compound, and an application. The sphingolipid compound is prepared by taking a long-chain alkyl group as a hydrophobic tail part, and bond...
|
|
WO/2023/185752A1 |
Disclosed in the present invention are a triazolamide compound, a preparation method therefor, and a use thereof. Specifically, disclosed are a triazolamide compound as shown in formula I or a pharmaceutically acceptable salt thereof, an...
|
|
WO/2023/190264A1 |
The present invention addresses the problem of providing: a novel triazole compound; a method for synthesizing the triazole compound; and a coupling agent. A triazole compound according to the present invention is represented by chemical...
|
|
WO/2023/183463A1 |
Provided herein is a method of potentiating a cytotoxic effect of temozolomide against glioblastoma cells in a subject in need thereof, the method including administering to the subject a combination of: a therapeutically effective amoun...
|
|
WO/2023/181075A1 |
The present application relates to amorphous solid dispersions of Deucravacitinib, process for the preparation of amorphous solid dispersion of Deucravacitinib, process for the preparation crystalline form of Deucravacitinib and process ...
|
|
WO/2023/179758A1 |
Disclosed in the present application is a crystal of a fused tricyclic derivative or a pharmaceutically acceptable salt thereof; and specifically disclosed are a crystal of a compound of formula (I), a crystal of a pharmaceutically accep...
|
|
WO/2023/177591A1 |
Described herein are a haloalkylpyridyl triazole MLL1-WDR5 protein-protein interaction inhibitors, pharmaceutical compositions and methods of use.
|
|
WO/2023/170543A1 |
The present invention relates to fluorinated amphiphilic dendrimer structures (FJDs) capable of self-assembling into supramolecular systems of different size and shape. A further object is a supramolecular complex comprising at least one...
|
|
WO/2023/166039A1 |
The present invention relates to compounds of formula (I) and the use thereof as inhibitors of P. aeruginosa virulence factor LasB. These compounds are useful in the treatment of bacterial infections, especially caused by P. aeruginosa.
|
|
WO/2023/166303A1 |
The invention relates to compounds of formula (I): (I) and related aspects.
|
|
WO/2023/165011A1 |
Disclosed in the present application are a cross-linking agent as well as a preparation method and the use thereof. The structure of the cross-linking agent contains triazolyl, and contains a double bond, amide acid or imide structure at...
|
|
WO/2023/160035A1 |
A β-elemene vinylation coupled derivative, and a preparation method therefor and the use thereof in the preparation of an antitumor drug. Provided are a β-elemene vinylation coupled derivative having a structure as represented by formu...
|
|
WO/2023/161023A1 |
The presently claimed invention relates to an ultraviolet absorber compound and a process for the preparation thereof.
|
|
WO/2023/158602A1 |
Disclosed are compounds of Formula I including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein G, Z, L, J, A and T are as defined in the disclosure. Also disclosed are compositions containing the compound...
|
|
WO/2023/156402A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description. The com...
|
|
WO/2023/157862A1 |
Provided is a method for producing α-fluoroether starting from an inactivated chloride. Disclosed is a method for producing a compound represented by formula (3), the method comprising step A in which a compound represented by formula (...
|
|
WO/2023/151640A1 |
Provided herein are compounds having the structure (I), wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.
|
|
WO/2023/151642A1 |
Provided herein are compounds having the following structure, wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.
|
|
WO/2023/144711A1 |
The present invention provides novel 1,2,3-triazole carbonyl sulfonylamide compounds of formula (I), Formula (I) wherein, R1, R2 and Z are as defined in the detailed description. The present invention further relates to their preparation...
|
|
WO/2023/146812A1 |
Methods of treating a subject for long-haul COVID are provided. Aspects of the methods include administering to the subject a tropane CCR5/CCL5 interaction inhibitor in combination with a statin to treat the subject for long-haul COVID. ...
|
|
WO/2023/146816A1 |
The present disclosure provides novel 4-substituted-phenyl acetamide and arylurea derivatives that act as agonists against GPR88. The compounds of the present disclosure are believed to be useful for the treatment of diseases and conditi...
|
|
WO/2023/140252A1 |
This material for controlling humidity contains a salt composed of specific triazolium cations and phosphate ester anions.
|
|
WO/2023/134629A1 |
The present disclosure relates to the field of drugs. Specifically, the present disclosure relates to a compound as represented by formula (I), or a stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug of the c...
|
|
WO/2023/128786A1 |
A family of triazole derivatives is described. Also described is the use of these triazole derivatives in treating or preventing viral infections, such as human immunodeficiency virus (HIV) infections, and the diseases caused by these in...
|
|
WO/2023/118434A1 |
The present invention relates to novel pesticidally active amide compounds and in particular heteroaromatic amide compounds, to compositions comprising those compounds, and to their use in agriculture, for example in controlling insect p...
|
|
WO/2023/122242A1 |
A method of attaching an azide moiety to a biomolecule. The method entails contacting a biomolecule in a solution with an azide and an oxidizing agent, for a time and at a temperature wherein at least one azide moiety is covalently bonde...
|
|
WO/2023/115203A1 |
Disclosed are compounds of formula (I), wherein ring A is an 8-10 membered aromatic or partially aromatic bicyclic ring having 1-4 heteroatoms compositions thereof, wherein L1, L2, R1 to R4 and m are as defined in claim 1; and methods of...
|
|
WO/2023/112038A1 |
The present invention is directed to 1,2,4 triazole derivatives and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a neutrophil-associated disease or condition in a subject in need th...
|
|
WO/2023/109878A1 |
A compound effectively antagonizing LPAR1. The compound is a compound represented by the following formula, or is a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt, or a prodrug of the compound represented by the f...
|
|
WO/2023/101463A1 |
In order to efficiently control microalgae and moss that cause problems in plant factories, intelligent smart farms, fish farms, living spaces, urban agriculture, etc., which are emerging as new industries, new alternative products that ...
|
|
WO/2023/101595A1 |
The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and bin...
|
|
WO/2023/094830A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R1, R2, R3 and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion ch...
|
|
WO/2023/092175A1 |
The invention relates generally to a compound of Formula (I), wherein R1 is a bicyclic fused heterocyclic moiety and R2 is H or F. The compound of Formula (I) or a pharmaceutically acceptable salt thereof has potential medical use in the...
|
|
WO/2023/094939A1 |
A novel dual-acting class of antifungal compound synthesized by linking an azole pharmacophore to a COX inhibitor to form a hybrid molecule. A method of making the antifungal compound by preparing a mixture of an azide-functionalized pha...
|
|
WO/2023/092715A1 |
Provided are an alanine aggregation-induced emission fluorescent probe (TPAPy-D-Ala) having a structure as represented by formula (I), and a synthesis method therefor and the use thereof. The synthesis method for TPAPy-D-Ala comprises: f...
|
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
|
WO/2023/088426A1 |
The present invention relates to the field of herbicides. Disclosed are an oxobutan(-2-enoic acid) acid compound and a preparation method therefor, a herbicidal composition and the use thereof, and a herbicide. The compound has a structu...
|
|
WO/2023/086547A1 |
Methods of preventing or treating a coronavirus infection or a herpes simplex virus infection in a subject or preventing or treating a disease caused by a coronavirus infection or a herpes simplex virus infection in a subject are disclos...
|
|
WO/2023/083983A1 |
The present invention thus provides a novel family of liposomal compositions (nanocarriers), hereinafter referred to as Tetra-Acidosomes, comprising natural tetrameric acid (TA) lipids and/or novel chemically functionalized tetrameric ac...
|
|
WO/2023/085246A1 |
A nonphotosensitive surface modifying agent according to the present invention is for forming a surface modification layer between a metal layer and a resin layer, and contains at least one heterocyclic compound having a structure repres...
|
|
WO/2023/080708A1 |
The present invention relates to a novel salt of 2-amino-2-(2-(1-decyl-1H-1,2,3-triazol-4-yl)ethyl)propane-1,
3-diol, and a pharmaceutical composition containing same. In the results of a comparison with hydrochloride salt of 2-amino-2-(...
|
|
WO/2023/078337A1 |
The disclosure provides for compounds and methods for modulating or inhibiting CDK8/19. In one aspect, described herein are compounds of Formula (A'), (A), (A-I), (A-II), (II), (II-I), (II-II), (III), (B), (IV), (V), (VI), and (VII), and...
|
|
WO/2023/078461A1 |
A heterocyclic compound as shown in formula I, a tautomer, stereoisomer, solvate, pharmaceutically acceptable salt or prodrug thereof, a preparation method therefor, and the use thereof. The heterocyclic compound has a better 15-PGDH inh...
|
|
WO/2023/070700A1 |
Provided are a compound using fluorene as a core, and a preparation method therefor and the use thereof. By means of changing the types of a donor and an acceptor and bonding positions, an electroluminescent device having a series of blu...
|
|
WO/2023/072248A1 |
Provided are a pyridyl-containing compound represented by formula I and a preparation method therefor, and the use thereof in the preparation for a drug for treating tumors.
|
|
WO/2023/076626A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/073115A1 |
The present invention relates to the use of the compound of the formula (I) and the composition thereof as control agent for plant diseases caused by fungi, oomycetes and bacteria. Plant pathogens produce self-aggregating proteins, like ...
|
|
WO/2023/066348A1 |
Provided are a new compound as represented by formula (I) having a dual antagonistic effect of an angiotensin II receptor and an endothelin receptor, and the use thereof in the preparation of a drug.
|
|
WO/2023/062627A1 |
Provided herein are compounds that inhibit the protein-protein interaction of serine acetyltransferase (SAT) with O-acetyl serine sulfhydrylase (OASS), and can therefore be used as herbicides.
|
